Skip to main content
Erschienen in: Current Allergy and Asthma Reports 2/2011

01.04.2011

The History of IgE: From Discovery to 2010

verfasst von: S. G. O. Johansson

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The discovery of IgE and the role of IgE-mediated inflammation gave clinical allergy a scientific backbone, and as a result, the reputation of the specialty allergy has increased considerably over the years. Allergy diagnosis was improved by assays for in vitro determination of the presence and concentration of IgE antibodies, and clinical knowledge also broadened, allowing better service for the increasing number of allergic individuals. Access to immune assays for allergens finally allowed characterization and standardization of allergen preparations used for diagnosis and allergen-specific immunotherapy. Improved basic molecular technologies have further increased our knowledge about the complex component composition of an allergen extract, introduced IgE-specific immunotherapy, and allowed the allergist to better handle even severe allergic reactions such as anaphylaxis.
Literatur
1.
Zurück zum Zitat Bostock J: Case of a periodical affection of the eyes and chest. Med Chir Trans 1819, 10:161.PubMed Bostock J: Case of a periodical affection of the eyes and chest. Med Chir Trans 1819, 10:161.PubMed
2.
Zurück zum Zitat Ramirez MA: Horse asthma following blood transfusion: Report on a case. JAMA 1919, 73:984–985. Ramirez MA: Horse asthma following blood transfusion: Report on a case. JAMA 1919, 73:984–985.
3.
Zurück zum Zitat Prausnitz C, Küstner H: Studien über die Überempfindlichkeit. Zentralbl Bakteriol I Abt Orig 1921, 86:160–169. Prausnitz C, Küstner H: Studien über die Überempfindlichkeit. Zentralbl Bakteriol I Abt Orig 1921, 86:160–169.
4.
Zurück zum Zitat Coca AF, Cooke RA: On the classification of the phenomenon of hypersensitiveness. J Immunol 1923, 8:163–182. Coca AF, Cooke RA: On the classification of the phenomenon of hypersensitiveness. J Immunol 1923, 8:163–182.
5.
Zurück zum Zitat Ishizaka K, Ishizaka T, Hathorn EM: Blocking of Prausnitz-Küstner sensitization with reagin by “A chain“ of human γ1A-globulin. Immunochemistry 1964, 1:197–207.PubMedCrossRef Ishizaka K, Ishizaka T, Hathorn EM: Blocking of Prausnitz-Küstner sensitization with reagin by “A chain“ of human γ1A-globulin. Immunochemistry 1964, 1:197–207.PubMedCrossRef
6.
Zurück zum Zitat Ishizaka K, Ishizaka T: Identification of γE-antibodies as a carrier of reaginic activity. J Immunol 1967, 99:1187.PubMed Ishizaka K, Ishizaka T: Identification of γE-antibodies as a carrier of reaginic activity. J Immunol 1967, 99:1187.PubMed
7.
Zurück zum Zitat Rowe DS, Fahey JL: A new class of human immunoglobulins. II. Normal serum IgD. J Exp Med 1965, 121:185–199.PubMedCrossRef Rowe DS, Fahey JL: A new class of human immunoglobulins. II. Normal serum IgD. J Exp Med 1965, 121:185–199.PubMedCrossRef
8.
Zurück zum Zitat Stanworth DR, Humphrey JH, Bennich H, Johansson SGO: Specific inhibition of the Prausnitz-Küstner reaction by an atypical human myeloma protein. Lancet 1967, 2:330–332.PubMedCrossRef Stanworth DR, Humphrey JH, Bennich H, Johansson SGO: Specific inhibition of the Prausnitz-Küstner reaction by an atypical human myeloma protein. Lancet 1967, 2:330–332.PubMedCrossRef
9.
Zurück zum Zitat Johansson SGO: Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967, 2:951–953.PubMedCrossRef Johansson SGO: Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967, 2:951–953.PubMedCrossRef
10.
Zurück zum Zitat Wide L, Bennich H, Johansson SGO: Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet 1967, 2:1105–1107.PubMedCrossRef Wide L, Bennich H, Johansson SGO: Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet 1967, 2:1105–1107.PubMedCrossRef
11.
Zurück zum Zitat Bennich HH, Ishizaka K, Johansson SGO, et al.: Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ 1968, 38:151–152. Bennich HH, Ishizaka K, Johansson SGO, et al.: Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ 1968, 38:151–152.
12.
Zurück zum Zitat Johansson SGO, Nopp A, van Hage M, et al.: Passive IgE-sensitization by blood transfusion. Allergy 2005, 60:1192–1199.PubMedCrossRef Johansson SGO, Nopp A, van Hage M, et al.: Passive IgE-sensitization by blood transfusion. Allergy 2005, 60:1192–1199.PubMedCrossRef
13.
Zurück zum Zitat Marsh DG: Allergens and the genetics of allergy. In: Sela M (ed.) The Antigens, vol. 3, Academic Press, New York, 1975, pp. 271–359. Marsh DG: Allergens and the genetics of allergy. In: Sela M (ed.) The Antigens, vol. 3, Academic Press, New York, 1975, pp. 271–359.
14.
Zurück zum Zitat Nopp A, Johansson SGO, Ankerst J, et al.: Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006, 61:298–302.PubMedCrossRef Nopp A, Johansson SGO, Ankerst J, et al.: Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006, 61:298–302.PubMedCrossRef
15.
Zurück zum Zitat Wang H, Diepgen TL: Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005, 60:1098–1111.PubMedCrossRef Wang H, Diepgen TL: Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005, 60:1098–1111.PubMedCrossRef
16.
Zurück zum Zitat Lindelöf B, Granath F, Tengvall-Linder M, Ekbom A: Allergy and cancer. Allergy 2005, 60:1116–1120. Lindelöf B, Granath F, Tengvall-Linder M, Ekbom A: Allergy and cancer. Allergy 2005, 60:1116–1120.
17.
Zurück zum Zitat Vohlonen I, Terho EO, Koivikko A, et al.: Reproducibility of the skin prick test. Allergy 1989, 44:525–531.PubMedCrossRef Vohlonen I, Terho EO, Koivikko A, et al.: Reproducibility of the skin prick test. Allergy 1989, 44:525–531.PubMedCrossRef
18.
Zurück zum Zitat Nelson HS, Oppenheimer J, Buchmeier A, et al.: An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. J Allergy Clin Immunol 1996, 97:1193–1201.PubMedCrossRef Nelson HS, Oppenheimer J, Buchmeier A, et al.: An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. J Allergy Clin Immunol 1996, 97:1193–1201.PubMedCrossRef
19.
Zurück zum Zitat Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities associated with immunotherapy and skin testing. J Allergy Clin Immunol 1987, 79:660–677.PubMedCrossRef Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities associated with immunotherapy and skin testing. J Allergy Clin Immunol 1987, 79:660–677.PubMedCrossRef
20.
Zurück zum Zitat Sampson HA, Ho DG: Relationship between food specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 1997, 100:444–451.PubMedCrossRef Sampson HA, Ho DG: Relationship between food specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 1997, 100:444–451.PubMedCrossRef
21.
Zurück zum Zitat Sampson HA: Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001, 107:891–896.PubMedCrossRef Sampson HA: Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001, 107:891–896.PubMedCrossRef
22.
Zurück zum Zitat Nopp A, Johansson SGO, Lundberg M, Öman H: Simultaneous exposure of several allergens has an additive effect on multisensitized basophils. Allergy 2006, 61:1366–1368.PubMedCrossRef Nopp A, Johansson SGO, Lundberg M, Öman H: Simultaneous exposure of several allergens has an additive effect on multisensitized basophils. Allergy 2006, 61:1366–1368.PubMedCrossRef
23.
Zurück zum Zitat Wahn U, Martin C, Freeman P, et al.: Relationship between pre-treatment specific IgE and the response to omalizumab therapy. Allergy 2009, 64:1780–1987.PubMedCrossRef Wahn U, Martin C, Freeman P, et al.: Relationship between pre-treatment specific IgE and the response to omalizumab therapy. Allergy 2009, 64:1780–1987.PubMedCrossRef
24.
Zurück zum Zitat Valenta R, Lidholm J, Niederberger V, et al.: The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999, 29:896–904.PubMedCrossRef Valenta R, Lidholm J, Niederberger V, et al.: The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999, 29:896–904.PubMedCrossRef
25.
Zurück zum Zitat Florvaag E, Johansson SGO: The pholcodine story. Immunol Allergy Clin North Am 2009, 29:419–427.PubMedCrossRef Florvaag E, Johansson SGO: The pholcodine story. Immunol Allergy Clin North Am 2009, 29:419–427.PubMedCrossRef
26.
Zurück zum Zitat •• Valenta R, Ferreira F, Focke-Tejkl M, et al.: From allergen genes to allergy vaccines. Ann Rev Immunol 2010, 28:211–241. This is an important summary of recent developments related to allergens. CrossRef •• Valenta R, Ferreira F, Focke-Tejkl M, et al.: From allergen genes to allergy vaccines. Ann Rev Immunol 2010, 28:211–241. This is an important summary of recent developments related to allergens. CrossRef
27.
Zurück zum Zitat Holgate ST, Chuchalin AG, Herbert J, et al.: Efficacy and safety of a recombinant anti-IgE antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632–638.PubMedCrossRef Holgate ST, Chuchalin AG, Herbert J, et al.: Efficacy and safety of a recombinant anti-IgE antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632–638.PubMedCrossRef
28.
Zurück zum Zitat Kleine-Tebbe J, Erdmann S, Knol EF, et al.: Diagnostic tests based human basophils: Potentials, pitfalls and perspectives. Int Arch Allergy Clin Immunol 2006, 141:79–90.CrossRef Kleine-Tebbe J, Erdmann S, Knol EF, et al.: Diagnostic tests based human basophils: Potentials, pitfalls and perspectives. Int Arch Allergy Clin Immunol 2006, 141:79–90.CrossRef
29.
Zurück zum Zitat •• Johansson SGO, Nopp A, Öman H, et al.: The size of the disease relevant IgE antibody fraction in relation to “total-IgE” predicts the efficacy of anti-IgE (Xolair®) treatment. Allergy 2009, 64:1472–1477. This study proofs that the dosage of anti-IgE must be linked to the size of the IgE antibody fraction. PubMedCrossRef •• Johansson SGO, Nopp A, Öman H, et al.: The size of the disease relevant IgE antibody fraction in relation to “total-IgE” predicts the efficacy of anti-IgE (Xolair®) treatment. Allergy 2009, 64:1472–1477. This study proofs that the dosage of anti-IgE must be linked to the size of the IgE antibody fraction. PubMedCrossRef
30.
Zurück zum Zitat Eckman JA, Sterba PM, Kelly D, et al.: Effects of Omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010, 125:889–895.PubMedCrossRef Eckman JA, Sterba PM, Kelly D, et al.: Effects of Omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010, 125:889–895.PubMedCrossRef
31.
Zurück zum Zitat Johansson SGO, Öman H, Nopp A, Pettersson S: The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006, 61:1216–1219.PubMedCrossRef Johansson SGO, Öman H, Nopp A, Pettersson S: The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006, 61:1216–1219.PubMedCrossRef
32.
Zurück zum Zitat Johansson SGO, Hourihane JO, Bousquet J, et al.: A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001, 56:813–824.PubMedCrossRef Johansson SGO, Hourihane JO, Bousquet J, et al.: A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001, 56:813–824.PubMedCrossRef
33.
Zurück zum Zitat •• Johansson SGO, Bieber, T, Dahl R, et al.: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004, 113:832–836. Without one and the same nomenclature we cannot communicate.PubMedCrossRef •• Johansson SGO, Bieber, T, Dahl R, et al.: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004, 113:832–836. Without one and the same nomenclature we cannot communicate.PubMedCrossRef
Metadaten
Titel
The History of IgE: From Discovery to 2010
verfasst von
S. G. O. Johansson
Publikationsdatum
01.04.2011
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 2/2011
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-010-0174-3

Weitere Artikel der Ausgabe 2/2011

Current Allergy and Asthma Reports 2/2011 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.